Conte PF - Search Results

1

Achievements and unmet needs in the management of advanced ovarian cancer.

Guarneri V, Piacentini F, Barbieri E, Conte PF. Guarneri V, et al. Among authors: conte pf. Gynecol Oncol. 2010 May;117(2):152-8. doi: 10.1016/j.ygyno.2009.11.033. Epub 2010 Jan 6. Gynecol Oncol. 2010. PMID: 20056266 Review.

2

Abdominopelvic radiotherapy following surgery and chemotherapy in advanced ovarian cancer.

Chiara S, Orsatti M, Franzone P, Scarpati D, Bruzzone M, Repetto L, Vitale V, Conte PF, Rosso R. Chiara S, et al. Among authors: conte pf. Clin Oncol (R Coll Radiol). 1991 Nov;3(6):340-4. doi: 10.1016/s0936-6555(05)80590-4. Clin Oncol (R Coll Radiol). 1991. PMID: 1742234

3

Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity.

Vigani A, Chiara S, Miglietta L, Repetto L, Conte PF, Cimoli G, Morelli L, Billi G, Parodi S, Russo P. Vigani A, et al. Among authors: conte pf. Gynecol Oncol. 1991 Apr;41(1):52-5. doi: 10.1016/0090-8258(91)90254-3. Gynecol Oncol. 1991. PMID: 2026360

4

Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look.

Bruzzone M, Repetto L, Chiara S, Campora E, Conte PF, Orsatti M, Vitale V, Rubagotti A, Rosso R. Bruzzone M, et al. Among authors: conte pf. Gynecol Oncol. 1990 Sep;38(3):392-5. doi: 10.1016/0090-8258(90)90080-5. Gynecol Oncol. 1990. PMID: 2227553 Clinical Trial.

5

Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V, Donadio G, Odicino F, Ragni N, Conte PF, et al. Repetto L, et al. Among authors: conte pf. Gynecol Oncol. 1990 Nov;39(2):146-9. doi: 10.1016/0090-8258(90)90422-h. Gynecol Oncol. 1990. PMID: 2227588 Clinical Trial.

6

Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.

Conte PF, Sertoli MR, Bruzzone M, Rubagotti A, Rosso R, Bentivoglio G, Conio A, Pescetto G. Conte PF, et al. Gynecol Oncol. 1985 Mar;20(3):290-7. doi: 10.1016/0090-8258(85)90210-0. Gynecol Oncol. 1985. PMID: 2982705

7

Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.

Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, Rosso R, Conte PF. Chiara S, et al. Among authors: conte pf. Eur J Cancer. 1995;31A(3):296-301. doi: 10.1016/0959-8049(94)00487-p. Eur J Cancer. 1995. PMID: 7786592 Clinical Trial.

8

Advanced ovarian cancer. Carboplatin versus cisplatin.

Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA, Favalli G, Belpomme D, Conte PF, Kaye SB. Vermorken JB, et al. Among authors: conte pf. Ann Oncol. 1993;4 Suppl 4:41-8. Ann Oncol. 1993. PMID: 8312200 Review.

9

The impact of received dose intensity on the outcome of advanced ovarian cancer.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al. Repetto L, et al. Among authors: conte pf. Eur J Cancer. 1993;29A(2):181-4. doi: 10.1016/0959-8049(93)90169-g. Eur J Cancer. 1993. PMID: 8422279 Clinical Trial.

10

Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.

Conte PF, Baldini E, Michelotti A, Salvadori B, Gennari A, Da Prato M, Tibaldi C, Giannessi PG, Gentile A. Conte PF, et al. Semin Oncol. 1996 Dec;23(6 Suppl 15):39-42. Semin Oncol. 1996. PMID: 8996597 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

475 results

Search Page